Hoppa till huvudinnehållet

CSL Behring announces closing of agreement with uniQure

CSL Behring has acquired the exclusive global license rights to commercialize etranacogene dezaparvovec, uniQure’s AAV5 (adeno-associated virus) gene therapy program, for the treatment of hemophilia B.

• Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.

• uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.


Read the full news release on MyNewdesk